1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Nu-Med Plus, Inc.

Nu-Med Plus, Inc.

NUMD
Nu-Med Plus, Inc.US flagOther OTC
0.02
USD
+0.00
- -
1.27MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.01
-0.04
-0.25
0.26
0.1
-0.03
-0.02
-0.04
-0.01
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
-0.01
- -
-0.01
- -
-0.01
-0.01
-0.01
-0.01
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.02
-0.05
-0.5
-0.22
-0.12
-0.14
-0.15
-0.16
-0.13
-0.12
-0.12
-0.12
-0.12
-0.12
Tangible Book Value per Share
- -
- -
-0.43
-0.12
- -
- -
-0.01
0.01
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
28
33
35
37
37
42
46
55
73
80
82
84
84
84
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-1
-9
10
4
-1
-1
-2
-1
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
-15
-4
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
-15
-4
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
24.52
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-77.1
-60.57
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
84
84
84
Market Capitalization
3
1
1

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-126.6%
4.97%
26.12%
Free Cash Flow
97.03%
166%
982.31%
Net Income, GAAP
-53.38%
-41.98%
-17.8%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
William R. Colvin
Full Time Employees
2
Sector
Healthcare
Industry
Medical - Devices
Address
455 East 500 South Port Jefferson NY United States of America 84111
IPO Date
Sep 25, 2014
CIK
0001543637
Website
nu-medplus.com
Similar Companies
Nihon Kohden Corporation (NHNKF)
CVR Medical Corp. (CRRVF)
Inspiration Healthcare Group plc (IHC.L)
Mauna Kea Technologies S.A. (MKEAF)
Boston Scientific Corporation (BSX)
Shenzhen Edge Medical Co Ltd (2675.HK)
Business
Nu-Med Plus, Inc. (NUMD) develops, enhances, and commercializes medical devices focused on nitric oxide delivery systems worldwide; its core products include a nitric oxide generating formulation, hospital bedside nitric oxide delivery systems, clinical units for medical clinics and rehabilitation centers, mobile rechargeable and portable devices to deliver inhaled nitric oxide gas, and research-grade nitric oxide systems. The company targets hospitals, health systems, clinics, rehabilitation centers, and research institutions, serving therapeutic applications such as neonatal hypoxia-ischemia, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and other pulmonary conditions benefiting from vasodilation and improved oxygenation. Founded in 2011 and headquartered at 640 Belle Terre Road, Building 2 East, Port Jefferson, New York, the firm operates primarily in the healthcare equipment segment of the medical devices industry with a small team of two employees. In recent developments, Nu-Med Plus reported a net loss of $43,564 for the nine months ended September 30, 2025, with no revenue generated as product development remains suspended pending approximately $1.2 million in additional funding over the next 12 months to cover overhead, operations, and advancement of its proprietary nitric oxide technologies. The company continues to emphasize its strategy of on-site nitric oxide generation to offer cost-effective alternatives to single-source market products like Inomax, positioning for potential partnerships with gas suppliers amid expanding medical applications, though it faces substantial going concern doubts without new capital via equity sales or shareholder loans. No acquisitions, partnerships, new product launches, or reorganizations have been announced in the last 1-2 years, with focus remaining on regulatory pathways including FDA approvals for hospital, clinical, and portable units.

Company News

APIChatGPT

  • newsfilecorp.com

    NU-Med Plus Announces Acquisition of Avid Gold and Agreement to Acquire Canadian Gold Properties